1. Home
  2. NSP vs DRUG Comparison

NSP vs DRUG Comparison

Compare NSP & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insperity Inc.

NSP

Insperity Inc.

HOLD

Current Price

$26.50

Market Cap

819.5M

ML Signal

HOLD

Logo Bright Minds Biosciences Inc.

DRUG

Bright Minds Biosciences Inc.

HOLD

Current Price

$70.10

Market Cap

707.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSP
DRUG
Founded
1986
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
819.5M
707.1M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
NSP
DRUG
Price
$26.50
$70.10
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$47.67
$124.00
AVG Volume (30 Days)
1.1M
93.1K
Earning Date
04-28-2026
05-14-2026
Dividend Yield
8.95%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$6,812,000,000.00
N/A
Revenue This Year
$3.45
N/A
Revenue Next Year
$6.95
N/A
P/E Ratio
N/A
N/A
Revenue Growth
3.51
N/A
52 Week Low
$18.57
$23.18
52 Week High
$90.63
$123.75

Technical Indicators

Market Signals
Indicator
NSP
DRUG
Relative Strength Index (RSI) 54.73 39.49
Support Level $18.57 $49.47
Resistance Level $48.91 $84.29
Average True Range (ATR) 1.72 3.95
MACD 1.15 -0.06
Stochastic Oscillator 84.65 9.69

Price Performance

Historical Comparison
NSP
DRUG

About NSP Insperity Inc.

Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: